Antibody development platform
Next Gen. CAR-T
Empowering to Combat Cancers Worldwide by Harnessing Enhanced Immunotherapy
-Practice of Chimeric Antigen Receptor T-cell Therapy
-Engagement of Next Generation Development
Chimeric Antigen Receptor (CAR-T) technology directs T cells to recognize cancer cells based on expression of specific cell surface proteins.
Collaborations enable us to strengthen the capabilities to accelerate the development process and scale commercialization in a much prosperous way.
CAR-T cell therapy plays a critical role in personalized and precision medicines in advancement of clinical performance for cancer patients.
Latest Press Releases
Dr. Li Zonghai gave speech at CAR-T TCR 2016 Annual Summit
CARsgen Therapeutics Completes $30 Million Series B Financing
CARsgen Enters into Partnership Agreement with Shanghai Cancer Institute and to Develop Novel CAR-T ...
CARsgen Completes Series A Financing
Dr. Zhi Yang was invited to take part in the 33rd Annual J.P. Morgan healthcare conference